Cargando…

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents s...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Steven, Cook, Joselle, Goulbourne, Clive, Meade, Matthew, Salciccioli, Louis, Lazar, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488311/
https://www.ncbi.nlm.nih.gov/pubmed/28695019
http://dx.doi.org/10.1155/2017/6458636